Literature DB >> 17216055

MALDI-TOF mass spectral analysis of siRNA degradation in serum confirms an RNAse A-like activity.

John J Turner1, Simon W Jones, Sterghios A Moschos, Mark A Lindsay, Michael J Gait.   

Abstract

Synthetic siRNA duplexes are used widely as reagents for silencing of mRNA targets in cells and are being developed for in vivo use. Serum stability is a major concern if siRNA is to be used for therapeutic delivery within blood circulation. We have developed the use of MALDI-TOF mass spectrometry as a rapid and convenient analytical tool to identify the most vulnerable sites within siRNA to serum degradation. Using this approach, we found that one siRNA duplex (Dh3) with UpA sequences close to one end was particularly vulnerable to rapid cleavage. This produced a fragment of mass consistent with the presence of a 2',3'-cyclic phosphate that was slowly hydrolysed to a 2'-(3'-)phosphate on extended incubation. Substitution of these sites with 2'-O-methyl U residues prevented cleavage and confirmed that the major pathway for initial degradation is via cleavage by an RNAse A-like activity. Mass spectral analysis was used to follow the serum degradation of siRNA over more prolonged periods to show the accumulation of many fragments, almost all showing cleavage following pyrimidine nucleoside residues. Overall, the MALDI-TOF mass spectral analysis technique should prove useful for preliminary screening of the serum stability of siRNA duplexes and for identification of the most vulnerable cleavage sites.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17216055      PMCID: PMC2682774          DOI: 10.1039/b611612d

Source DB:  PubMed          Journal:  Mol Biosyst        ISSN: 1742-2051


  17 in total

Review 1.  The design and exogenous delivery of siRNA for post-transcriptional gene silencing.

Authors:  Ian R Gilmore; Stephen P Fox; Andrew J Hollins; Muhammad Sohail; Saghir Akhtar
Journal:  J Drug Target       Date:  2004-07       Impact factor: 5.121

2.  Inhibition of RNAse A family enzymes prevents degradation and loss of silencing activity of siRNAs in serum.

Authors:  Jörg Haupenthal; Christina Baehr; Simone Kiermayer; Stefan Zeuzem; Albrecht Piiper
Journal:  Biochem Pharmacol       Date:  2006-01-10       Impact factor: 5.858

3.  Fully 2'-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA.

Authors:  Charles R Allerson; Namir Sioufi; Russell Jarres; Thazha P Prakash; Nishant Naik; Andres Berdeja; Lisa Wanders; Richard H Griffey; Eric E Swayze; Balkrishen Bhat
Journal:  J Med Chem       Date:  2005-02-24       Impact factor: 7.446

4.  Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs.

Authors:  David V Morrissey; Jennifer A Lockridge; Lucinda Shaw; Karin Blanchard; Kristi Jensen; Wendy Breen; Kimberly Hartsough; Lynn Machemer; Susan Radka; Vasant Jadhav; Narendra Vaish; Shawn Zinnen; Chandra Vargeese; Keith Bowman; Chris S Shaffer; Lloyd B Jeffs; Adam Judge; Ian MacLachlan; Barry Polisky
Journal:  Nat Biotechnol       Date:  2005-07-24       Impact factor: 54.908

5.  Oligonucleotide inhibition of the interaction of HIV-1 Tat protein with the trans-activation responsive region (TAR) of HIV RNA.

Authors:  B Mestre; A Arzumanov; M Singh; F Boulmé; S Litvak; M J Gait
Journal:  Biochim Biophys Acta       Date:  1999-04-14

6.  Chemical modification of siRNAs to improve serum stability without loss of efficacy.

Authors:  Sorim Choung; Young Joo Kim; Seonhoe Kim; Han-Oh Park; Young-Chul Choi
Journal:  Biochem Biophys Res Commun       Date:  2006-04-14       Impact factor: 3.575

7.  Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs.

Authors:  Jürgen Soutschek; Akin Akinc; Birgit Bramlage; Klaus Charisse; Rainer Constien; Mary Donoghue; Sayda Elbashir; Anke Geick; Philipp Hadwiger; Jens Harborth; Matthias John; Venkitasamy Kesavan; Gary Lavine; Rajendra K Pandey; Timothy Racie; Kallanthottathil G Rajeev; Ingo Röhl; Ivanka Toudjarska; Gang Wang; Silvio Wuschko; David Bumcrot; Victor Koteliansky; Stefan Limmer; Muthiah Manoharan; Hans-Peter Vornlocher
Journal:  Nature       Date:  2004-11-11       Impact factor: 49.962

8.  Functional polarity is introduced by Dicer processing of short substrate RNAs.

Authors:  Scott D Rose; Dong-Ho Kim; Mohammed Amarzguioui; Jeremy D Heidel; Michael A Collingwood; Mark E Davis; John J Rossi; Mark A Behlke
Journal:  Nucleic Acids Res       Date:  2005-07-26       Impact factor: 16.971

9.  Synthesis, cellular uptake and HIV-1 Tat-dependent trans-activation inhibition activity of oligonucleotide analogues disulphide-conjugated to cell-penetrating peptides.

Authors:  John J Turner; Andrey A Arzumanov; Michael J Gait
Journal:  Nucleic Acids Res       Date:  2005-01-07       Impact factor: 16.971

10.  Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality.

Authors:  Joacim Elmén; Håkan Thonberg; Karl Ljungberg; Miriam Frieden; Majken Westergaard; Yunhe Xu; Britta Wahren; Zicai Liang; Henrik Ørum; Troels Koch; Claes Wahlestedt
Journal:  Nucleic Acids Res       Date:  2005-01-14       Impact factor: 16.971

View more
  35 in total

1.  Duplex end breathing determines serum stability and intracellular potency of siRNA-Au NPs.

Authors:  Pinal C Patel; Liangliang Hao; Weng Si Au Yeung; Chad A Mirkin
Journal:  Mol Pharm       Date:  2011-06-28       Impact factor: 4.939

2.  Poly-L-arginine and dextran sulfate-based nanocomplex for epidermal growth factor receptor (EGFR) siRNA delivery: its application for head and neck cancer treatment.

Authors:  Hyun-Jong Cho; Saeho Chong; Suk-Jae Chung; Chang-Koo Shim; Dae-Duk Kim
Journal:  Pharm Res       Date:  2011-12-15       Impact factor: 4.200

Review 3.  Action and reaction: the biological response to siRNA and its delivery vehicles.

Authors:  Rosemary L Kanasty; Kathryn A Whitehead; Arturo J Vegas; Daniel G Anderson
Journal:  Mol Ther       Date:  2012-01-17       Impact factor: 11.454

4.  Monitoring the Photocleaving Dynamics of Colloidal MicroRNA-Functionalized Gold Nanoparticles Using Second Harmonic Generation.

Authors:  Raju R Kumal; Corey R Landry; Mohammad Abu-Laban; Daniel J Hayes; Louis H Haber
Journal:  Langmuir       Date:  2015-09-03       Impact factor: 3.882

Review 5.  Synthetic nucleic acids delivered by exosomes: a potential therapeutic for generelated metabolic brain diseases.

Authors:  Rutao Liu; Jing Liu; Xiaofei Ji; Yang Liu
Journal:  Metab Brain Dis       Date:  2013-12       Impact factor: 3.584

6.  Chemical modification resolves the asymmetry of siRNA strand degradation in human blood serum.

Authors:  John A H Hoerter; Nils G Walter
Journal:  RNA       Date:  2007-09-05       Impact factor: 4.942

7.  Improving gene silencing of siRNAs via tricyclo-DNA modification.

Authors:  Damian Ittig; Samuel Luisier; Jan Weiler; Daniel Schümperli; Christian J Leumann
Journal:  Artif DNA PNA XNA       Date:  2010-07

Review 8.  Progress toward in vivo use of siRNAs-II.

Authors:  Garrett R Rettig; Mark A Behlke
Journal:  Mol Ther       Date:  2011-12-20       Impact factor: 11.454

9.  Short interfering RNA guide strand modifiers from computational screening.

Authors:  Kazumitsu Onizuka; Jason G Harrison; Alexi A Ball-Jones; José M Ibarra-Soza; Yuxuan Zheng; Diana Ly; Walter Lam; Stephanie Mac; Dean J Tantillo; Peter A Beal
Journal:  J Am Chem Soc       Date:  2013-11-05       Impact factor: 15.419

10.  Solid polymeric microparticles enhance the delivery of siRNA to macrophages in vivo.

Authors:  Sungmun Lee; Stephen C Yang; Chen-Yu Kao; Robert H Pierce; Niren Murthy
Journal:  Nucleic Acids Res       Date:  2009-12       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.